By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Planning for Phase 3 Registration Trial ...

The oral presentation, titled, “¹⁸⁶Rhenium-Nanoliposomes (¹⁸⁶RNL) for the Treatment of Leptomeningeal Metastases: Translational Insights from Clinical and Preclinical Models,” was delivered by ...

Cloud-Clone has built an integrated antibody R&D and manufacturing platform, focusing on enhancing product consistency and MP for research and diagnostics. HUSTON, TX, UNITED STAT ...

Cubit Diagnostics today announced it has closed its latest round of SAFE (Simple Agreement for Future Equity) financing. The proceeds will fund the company's next phase of work, centered on locking in ...

When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...

New service offering enables GR/NF-κB transrepression studies to support deeper mechanism-of-action insight in drug ...

Operational sequencing of permitting workstreams ahead of a 27,000-foot Pre-Feasibility Study drill program is consistent with a credible ...

LiquidCell Dx, a next generation cancer diagnostics company, today announced publication in Nature of critical research underpinning the development of LiquidTME, its blood-based assay for tumor ...

The two partners will collaborate on the customization of IMSR Plants to be integrated with Riot developed and operated data centers. This partnership combines Terrestrial Energy's nuclear plant ...

Smaller life science plays adopting AI in earnest are attracting increased investor attention – but they need to keep their ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical data demonstrating low reactive ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.